metformin has been researched along with alprostadil in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Ning, G; Zhang, YF | 1 |
| Ai, X; Gao, Y; Li, C; Li, L; Sun, N; Sun, W; Wang, J | 1 |
1 review(s) available for metformin and alprostadil
| Article | Year |
|---|---|
Mecobalamin.
Topics: Aged; Alprostadil; Animals; Cobamides; Coenzymes; Diabetic Neuropathies; Drug Administration Routes; Drug Therapy, Combination; Female; Folic Acid; Humans; Hyperhomocysteinemia; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Metformin; Methionine; Methyltransferases; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Renal Dialysis; Vitamin B 12; Vitamin B 12 Deficiency; Vitamin B 6 | 2008 |
1 trial(s) available for metformin and alprostadil
| Article | Year |
|---|---|
Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy.
Topics: Aged; Alprostadil; Contrast Media; Creatinine; Diabetes Mellitus, Type 2; Emergencies; Female; Fluid Therapy; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Metformin; Middle Aged; Single-Blind Method; Tomography, X-Ray Computed; Urological Agents | 2017 |
3 other study(ies) available for metformin and alprostadil
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |